PPARG and type 2 diabetes mellitus: Originally, thiazolidinediones (TZDs), synthetic PPARγ activators, have been used for the treatment of patients with type II diabetes through modulating PPARγ-targeted genes including cyclin D1, inflammatory cytokines, and NF-κB [5,6].